Search Results for: Aged

Cost-effectiveness, public health impact, and budget impact of receipt of Pfizer-BioNTech COVID-19 vaccine, LP.8.1-adapted, 2025/2026 formula among adults aged 18 years and older at high risk for severe outcomes from COVID-19 in the United States.

Cost-effectiveness, public health impact, and budget impact of receipt of Pfizer-BioNTech COVID-19 vaccine, LP.8.1-adapted, 2025/2026 formula among adults aged 18 years and older at high risk for severe outcomes from COVID-19 in the United States.

Coronavirus Literature
Publication date: Dec 01, 2026 To assess the cost-effectiveness, public health impact, and budget impact of receiving the LP. 8.1-adapted Pfizer-BioNTech COVID-19 Vaccine among United States adults aged ≥ 18 years. ... Read more